[go: up one dir, main page]

CY1115407T1 - Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων - Google Patents

Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων

Info

Publication number
CY1115407T1
CY1115407T1 CY20141100569T CY141100569T CY1115407T1 CY 1115407 T1 CY1115407 T1 CY 1115407T1 CY 20141100569 T CY20141100569 T CY 20141100569T CY 141100569 T CY141100569 T CY 141100569T CY 1115407 T1 CY1115407 T1 CY 1115407T1
Authority
CY
Cyprus
Prior art keywords
soft tissue
thorio
subject
amount
tissue radiation
Prior art date
Application number
CY20141100569T
Other languages
English (en)
Inventor
Roy Larsen
Oyvind Bruland
Original Assignee
Algeta Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta Asa filed Critical Algeta Asa
Publication of CY1115407T1 publication Critical patent/CY1115407T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση παρέχει μία μέθοδο για την αγωγή ασθενειών των μαλακών ιστών σε ένα θηλαστικό υποκείμενο (κατά προτίμηση το υποκείμενο είναι ένας άνθρωπος ή ένας σκύλος), όπου η εν λόγω μέθοδος περιλαμβάνει τη χορήγηση στο εν λόγω υποκείμενο μίας θεραπευτικά δραστικής ποσότητας ενός στοχεύοντος τους μαλακούς ιστούς συμπλόκου θορίου-227 και ενός συμπλοκοποιητή, όπου η εν λόγω ποσότητα είναι τέτοια ώστε να παράγεται in vivo μία αποδεκτά μη μυελοτοξική ποσότητα ραδίου-223 μέσω πυρηνικής διασπάσεως του χορηγούμενου θορίου-227.
CY20141100569T 2003-04-15 2014-07-28 Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων CY1115407T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
EP04727587.0A EP1617876B1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (1)

Publication Number Publication Date
CY1115407T1 true CY1115407T1 (el) 2017-01-04

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100569T CY1115407T1 (el) 2003-04-15 2014-07-28 Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων

Country Status (18)

Country Link
EP (1) EP1617876B1 (el)
JP (2) JP5006032B2 (el)
KR (2) KR101274867B1 (el)
CN (1) CN100586484C (el)
AU (1) AU2004229218B2 (el)
BR (1) BRPI0409387B8 (el)
CA (1) CA2522148C (el)
CY (1) CY1115407T1 (el)
DK (1) DK1617876T3 (el)
EA (1) EA008195B1 (el)
ES (1) ES2486845T3 (el)
IL (1) IL171148A (el)
MX (1) MXPA05010804A (el)
NO (1) NO332931B1 (el)
NZ (3) NZ543044A (el)
PL (1) PL1617876T3 (el)
PT (1) PT1617876E (el)
ZA (1) ZA200507983B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543044A (en) * 2003-04-15 2010-04-30 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
WO2018109667A1 (en) 2016-12-15 2018-06-21 Nestec Sa Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69007430T2 (de) * 1989-06-19 1994-07-07 Akzo Nobel N.V., Arnheim/Arnhem Radioimmuntherapie unter alphapartikelausstrahlung.
SG52470A1 (en) * 1992-04-13 1998-09-28 Dow Chemical Co Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
CN1073860C (zh) * 1998-08-20 2001-10-31 中国核动力研究设计院 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
HUP0203743A2 (en) * 2000-02-25 2003-02-28 R Keith Frank Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
NZ543044A (en) * 2003-04-15 2010-04-30 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
NO20055390D0 (no) 2005-11-15
JP5006032B2 (ja) 2012-08-22
IL171148A (en) 2013-12-31
NZ595758A (en) 2013-02-22
CN100586484C (zh) 2010-02-03
NZ543044A (en) 2010-04-30
ES2486845T3 (es) 2014-08-19
EP1617876B1 (en) 2014-05-14
BRPI0409387A (pt) 2006-04-18
KR20060015507A (ko) 2006-02-17
AU2004229218B2 (en) 2009-05-07
CA2522148A1 (en) 2004-10-28
BRPI0409387B1 (pt) 2021-05-11
HK1094150A1 (zh) 2007-03-23
PL1617876T3 (pl) 2015-03-31
KR20110022743A (ko) 2011-03-07
PT1617876E (pt) 2014-08-04
MXPA05010804A (es) 2006-03-09
ZA200507983B (en) 2007-03-28
NO332931B1 (no) 2013-02-04
JP2006523664A (ja) 2006-10-19
DK1617876T3 (da) 2014-07-21
NZ606996A (en) 2014-08-29
AU2004229218A1 (en) 2004-10-28
JP2012051942A (ja) 2012-03-15
EA008195B1 (ru) 2007-04-27
CA2522148C (en) 2010-07-13
KR101274867B1 (ko) 2013-06-13
EA200501456A1 (ru) 2006-06-30
EP1617876A1 (en) 2006-01-25
BRPI0409387B8 (pt) 2021-05-25
JP5468597B2 (ja) 2014-04-09
CN1805760A (zh) 2006-07-19
NO20055390L (no) 2006-01-16

Similar Documents

Publication Publication Date Title
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
ATE305313T1 (de) Radiotherapy
ATE523224T1 (de) Verifizierung von läsionsmerkmalen mit strahlformen
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
CR8380A (es) Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos
Cengel et al. PDT: what's past is prologue
BR9914969A (pt) Métodos para formar imagem, tratar e localizar tecido doente, e, dispositivo integrado de formação de imagem e de tratamento
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
ID22689A (id) Metode untuk mengaktifkan sel-sel yang menunjukan-sifat antigen manusia, sel-sel teraktifkan yang menunjukan sifat antigen manusia, dan penggunaannya
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
CY1113489T1 (el) Αντισωμα το οποιο δεσμευει αλφα4βητα7 ιντεγκρινη και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CR8396A (es) Anticuerpos que se unen al receptor del interleuquina-4
CY1107084T1 (el) Παραγωγα πυρρολοπυριδαζινης
DK1217943T3 (da) Fremgangsmåde og apparat til bestemmelse af autofluorescens af hudvæv
CY1110341T1 (el) Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας
UY29284A1 (es) Anticuerpos ab(beta) humanizados usados en mejorar la cognicion
CY1114644T1 (el) Χρηση ραδιοεπισημασμενων παραγωγων θειοφλαβινης στην απεικονιση αμυλοειδους για την αξιολογηση αντι-αμυλοειδικων θεραπειων
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
BRPI0607460A2 (pt) braquiterapia periférica de órgãos protrusos moldáveis
DK1699480T3 (da) Allogent terapeutisk tumormiddel
CY1119790T1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
Morton et al. Review of the European society for photodynamic therapy (Euro-PDT) annual congress 2022